Tempus AI executive granted 13,642 RSUs

Schoenherr Thomas Edward reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Schoenherr Thomas Edward reported acquisition or exercise transactions in this Form 4 filing.

Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, received an equity award reported as 13,642 shares of Class A Common Stock. This represents two restricted stock unit grants: 3,642 RSUs are fully vested, and 10,000 RSUs will vest in eight equal quarterly installments starting on November 15, 2026. Following this grant, Schoenherr directly holds 108,609 shares of Class A Common Stock. The transaction reflects a compensation-related share award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 13,642 shares

Grant/Award 1 txn

Insider Schoenherr Thomas Edward

Role CEO, Diagnostics

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	13,642	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 108,609 shares (Direct)

Footnotes (1)

1. F1. Represents two restricted stock unit ("RSU") grants, consisting of (i) 3,642 RSUs that are fully vested, and (ii) 10,000 RSUs, which vest in eight equal quarterly installments commencing on November 15, 2026.

Key Figures

RSU grant size: 13,642 shares Fully vested RSUs: 3,642 shares Unvested RSUs: 10,000 shares +3 more

6 metrics

RSU grant size 13,642 shares Total Class A Common Stock RSUs granted on May 4, 2026

Fully vested RSUs 3,642 shares Portion of RSU award that is fully vested at grant

Unvested RSUs 10,000 shares RSUs vesting in eight equal quarterly installments starting November 15, 2026

Post-transaction holdings 108,609 shares Class A Common Stock directly held after the RSU grant

Grant price per share $0.00 per share Reported transaction price for RSU grant

Vesting start date November 15, 2026 Commencement of quarterly vesting for 10,000 RSUs

Key Terms

restricted stock unit ("RSU"), vested, quarterly installments, grant, award, or other acquisition, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents two restricted stock unit ("RSU") grants, consisting of (i) 3,642 RSUs"

vested financial

"3,642 RSUs that are fully vested, and (ii) 10,000 RSUs, which vest"

quarterly installments financial

"10,000 RSUs, which vest in eight equal quarterly installments"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tempus AI (TEM) report for Thomas Schoenherr?

Tempus AI reported that Thomas Edward Schoenherr, CEO of Diagnostics, received an equity award of 13,642 shares of Class A Common Stock as restricted stock units. The award is compensation-related and not an open-market buy or sell transaction.

How many Tempus AI (TEM) shares does Thomas Schoenherr hold after this Form 4?

After the reported transaction, Thomas Edward Schoenherr directly holds 108,609 shares of Tempus AI Class A Common Stock. This figure reflects his position following the RSU grant disclosed in the Form 4 insider filing.

How are the new Tempus AI (TEM) RSUs for Thomas Schoenherr structured?

The filing shows 13,642 RSUs, split between 3,642 RSUs that are fully vested and 10,000 RSUs that vest in eight equal quarterly installments. Vesting for the 10,000-unit grant begins on November 15, 2026, according to the disclosure.

Is the Tempus AI (TEM) Form 4 for Thomas Schoenherr an open-market purchase?

No. The Form 4 describes a grant or award acquisition of restricted stock units at a stated price of $0.00 per share. It reflects equity compensation, not an open-market purchase of Tempus AI shares by the executive.

When do Thomas Schoenherr’s unvested Tempus AI (TEM) RSUs start vesting?

The 10,000 unvested restricted stock units begin vesting on November 15, 2026. They vest in eight equal quarterly installments after that date, as specified in the Form 4 footnote describing the structure of the RSU grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoenherr Thomas Edward

(Last) (First) (Middle)

C/O TEMPUS AI, INC.

600 WEST CHICAGO AVENUE, SUITE 510

(Street)

CHICAGO ILLINOIS 60654

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tempus AI, Inc. [ TEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Diagnostics

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/04/2026		A		13,642(1)	A	$0	108,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents two restricted stock unit ("RSU") grants, consisting of (i) 3,642 RSUs that are fully vested, and (ii) 10,000 RSUs, which vest in eight equal quarterly installments commencing on November 15, 2026.

	/s/ Andrew Polovin, Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)